To address which WM lesions can be potentially targeted by BTKi, we compared BTK expression in 73 different WM lesions in postmortem brain samples from progressive MS: NAWM, active lesions, chronic active lesions, inactive lesions and remyelinating lesions. The gene discussed is BTK; the disease is myeloid sarcoma.